Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Fig. 5

Pharmacological modulation of the tumor immune contexture and response to checkpoint blockers. a Changes in the immune contexture of melanoma tumors during treatment with BRAF and/or MEK inhibitors, measured as “relative cell fraction variation”, i.e., ratio between the difference and the mean of the on- and pre-treatment immune cell fractions estimated via deconvolution. Immune cell fractions (log scale) estimated with quanTIseq from pre- (b) and on-treatment (c) samples collected from melanoma patients treated with anti-PD1 and stratified as responders (R) and non-responders (NR) (data from [58]). d quanTIseq immune cell densities (log scale) from our cohort of melanoma patients, stratified as responders (R) and non-responders (NR). Total cell densities used to scale quanTIseq immune cell fractions were estimated as the median number of nuclei per mm2 across all images generated from each tumor. B, B cells; CD4, total CD4+ T cells (including also CD4+ regulatory T cells); CD8, CD8+ T cells; DC, dendritic cells; M1, classically activated macrophages; M2, alternatively activated macrophages; Mono, monocytes; Neu, neutrophils; NK, natural killer cells; Treg, regulatory T cells; Other, other uncharacterized cells

Back to article page